Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction on Friday, October 4th. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00. Following the sale, the insider now owns 42,246 shares in the company, valued at $2,028,230.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total value of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Price Performance

RxSight stock opened at $49.90 on Friday. RxSight, Inc. has a 1-year low of $20.66 and a 1-year high of $66.54. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -39.60 and a beta of 1.20. The firm has a 50 day simple moving average of $51.63 and a 200-day simple moving average of $53.83.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The business had revenue of $34.89 million during the quarter, compared to analysts’ expectations of $32.33 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. The company’s revenue was up 67.6% on a year-over-year basis. Equities analysts expect that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RXST shares. BTIG Research upped their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Oppenheimer dropped their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Wells Fargo & Company lowered their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Stifel Nicolaus reduced their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $60.14.

Institutional Investors Weigh In On RxSight

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Amalgamated Bank grew its holdings in shares of RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after buying an additional 207 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of RxSight by 3.2% in the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after purchasing an additional 242 shares in the last quarter. RiverPark Advisors LLC lifted its holdings in RxSight by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after purchasing an additional 297 shares in the last quarter. CWM LLC boosted its holdings in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in RxSight by 5.0% in the second quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock valued at $467,000 after purchasing an additional 373 shares during the period. 78.78% of the stock is currently owned by institutional investors and hedge funds.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.